-
公开(公告)号：US11952420B2
公开(公告)日：2024-04-09
申请号：US17472051
申请日：2021-09-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Achal Pashine , Michael L Gosselin , Aaron P. Yamniuk , Derek A. Holmes , Guodong Chen , Priyanka Apurva Madia , Richard Yu-Cheng Huang , Stephen Michael Carl
CPC classification number: C07K16/2803 , A61K47/6803 , A61P29/00 , C12N15/85 , C07K2317/32 , C07K2317/565 , C07K2317/90 , C07K2317/92
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
公开(公告)号：US11213586B2
公开(公告)日：2022-01-04
申请号：US15776591
申请日：2016-11-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla A. Henning , Michelle Minhua Han , Guodong Chen , Richard Y. Huang , Indrani Chakraborty , Haichun Huang , Susan Chien-Szu Wong , Huiming Li , Bryan C. Barnhart , Aaron P. Yamniuk , Ming Lei , Liang Schweizer , Sandra V. Hatcher , Arvind Rajpal
IPC: C07K16/28 , A61K39/395 , G01N33/574 , G01N33/68 , A61K39/00
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20190248911A1
公开(公告)日：2019-08-15
申请号：US16399379
申请日：2019-04-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Bryan C. Barnhart , Brigitte Devaux , Aaron P. Yamniuk , Shannon L. Okada , Brenda L. Stevens
CPC classification number: C07K16/2878 , A61K2039/505 , A61P31/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US10245302B2
公开(公告)日：2019-04-02
申请号：US15282277
申请日：2016-09-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: C12P21/02 , C07K14/78 , A61K38/39 , C07K16/46 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17 , A61K47/64 , A61K47/60 , A61K47/48 , A61K38/00
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20190062456A1
公开(公告)日：2019-02-28
申请号：US16117183
申请日：2018-08-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/40 , G01N33/573 , A61K45/06 , C07K16/28 , C07K16/30 , A61K39/395 , A61K39/00
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
Patent Agency Ranking
公开(公告)号：US10100129B2
公开(公告)日：2018-10-16
申请号：US15520638
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: A61K39/00 , C07K16/40 , C07K16/28 , A61K47/68 , C07K16/30 , A61K39/395 , A61K45/06 , G01N33/574
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
-
公开(公告)号：US20160376371A1
公开(公告)日：2016-12-29
申请号：US15195098
申请日：2016-06-28
Applicant: The Rockefeller University , BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jeffrey V. Ravetch , Rony Dahan , Bryan C. Barnhart , Brigitte Devaux , Aaron P. Yamniuk , Shannon L. Okada , Brenda L. Stevens
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/72 , C07K2317/73 , C07K2317/75 , C07K2317/92
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Abstract translation: 本文提供了结合人CD40的激动性抗体或其抗原结合部分。 此类抗体任选地包含对FcγRIIb具有增强的特异性的Fc区。 本发明还提供了通过将本发明的抗体给予有需要的受试者来治疗癌症或慢性感染的方法。
-
公开(公告)号：US09493546B2
公开(公告)日：2016-11-15
申请号：US14481641
申请日：2014-09-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: A61K38/00 , C07K1/00 , C07K14/00 , C07K17/00 , C07K16/00 , C12P21/08 , A61K35/14 , C07K14/78 , C07K16/46 , A61K38/39 , A61K47/48 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20160145350A1
公开(公告)日：2016-05-26
申请号：US14994828
申请日：2016-01-13
Applicant: Bristol-Myers Squibb Company
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher
IPC: C07K16/40 , G01N33/573 , A61K39/395 , A61K47/48 , C07K16/30 , A61K45/06
CPC classification number: C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/573 , G01N2333/916
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Abstract translation: 本发明提供分离的单克隆抗体，特别是人抗体，其以高亲和力结合人类分化簇73（CD73），并且抑制CD73的活性，并任选介导抗体依赖性CD73内化。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体抑制表达CD73的肿瘤细胞生长的方法，包括治疗各种癌症的方法。
-
公开(公告)号：US11919954B2
公开(公告)日：2024-03-05
申请号：US17472302
申请日：2021-09-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Achal Pashine , Michael L. Gosselin , Aaron P. Yamniuk , Derek A. Holmes , Guodong Chen , Priyanka Apurva Madia , Richard Yu-Cheng Huang , Stephen Michael Carl
CPC classification number: C07K16/2803 , A61K47/6803 , A61P29/00 , C12N15/85 , C07K2317/32 , C07K2317/565 , C07K2317/90 , C07K2317/92
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.039 seconds)
